Rohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, Phyllis Thangaraj, Aroldo F. Camargos, Fan Bu, X. X. Ding, Akihiko Nishimura, Tara V. Anand, Faaizah Arshad, Clair Blacketer, Yu-Shuang Chai,
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and ot...